"Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00214656|
Recruitment Status : Unknown
Verified September 2005 by Austin Health.
Recruitment status was: Recruiting
First Posted : September 22, 2005
Last Update Posted : September 22, 2005
Aims and Hypotheses:
This randomised placebo controlled study will test the hypothesis that Recombinant Activated Factor VII (rVIIa) will improve haemostasis after an inadequate response to conventional therapy in complex cardiac surgery.
Major bleeding is still of concern in complex cardiac surgery. It has been shown to be associated with poorer patient outcome and results in the consumption of resources (hospital costs, manpower and blood bank reserves). This study has the potential to provide evidence that rVIIa can reduce transfusion requirements and improve patient outcome in a problematic aspect of complicated cardiac surgery.
The objective is to conduct a multi-centre randomised placebo controlled study that has been designed to scientifically evaluate the treatment of post bypass coagulopathy in the association with complex cardiac surgery. The trial design is based on clinical practice that has evolved over 2 years at the Austin Hospital during which 38 patients have received open label administration of rVIIa. There is currently no published RCT in this area and there is no TGA approval for the use of rVIIa for this indication.
|Condition or disease||Intervention/treatment||Phase|
|Myocardial Ischemia Blood Coagulation Disorders Coronary Artery Disease Heart Valve Diseases||Drug: Recombinant Activated Factor VII||Phase 3|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||"Salvage Use" of Recombinant Activated Factor VII After Inadequate Haemostatic Response to Conventional Therapy in Complex Cardiac Surgery - a Randomised Placebo Controlled Trial|
|Study Start Date :||June 2005|
|Estimated Study Completion Date :||June 2008|
- Adequate haemostasis to enable chest closure after administration of trial medication without the need for further intervention to improve coagulation.
- Percentage of cases that haemostasis after first administration of coagulation factors alone
- Assessment of surgical field after administration of trial medication
- Time to closure of chest after administration of trial medication
- Transfusion requirements in post bypass period in theatre
- Transfusion requirements in ICU first 12 hours
- Mediastinal drainage in ICU first 12 hours
- Coagulation study results at various sample times
- Requirement for chest re-exploration
- Ventilation duration in ICU
- Duration of stay in ICU
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00214656
|Contact: Peter McCall, FANZCA||61 3 94965000 ext firstname.lastname@example.org|
|Contact: stephanie j Poustie, MPH||61 3 94965000 ext email@example.com|
|Melbourne, Victoria, Australia, 3084|
|Contact: Peter McCall, FANZCA 61 3 94965000 ext 3800 firstname.lastname@example.org|
|Contact: Stephanie J Poustie, MPH 61 3 94965000 ext 3800 email@example.com|
|Principal Investigator: Peter McCall, FANZCA|
|Principal Investigator:||Peter McCall, FANZCA||Staff Anaesthetist|